Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sitafloxacin for refractory urinary tract infection
jRCTs061200052Completed
- Start
- Apr 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sitafloxacin in complicated urinary tract infection (cUTI), urinary tract infection (UTI), pyelonephritis and 2 more. Primary endpoint: Primary microbiological outcome at 5–9 days post-treatment. Started Apr 2021; status: completed.
02
Drugs
sitafloxacin
03
Conditions
complicated urinary tract infection (cUTI)urinary tract infection (UTI)pyelonephritisprostatitisepididymitis
Beyond the preview
Go deeper on jRCTs061200052.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs061200052.